ArticleProteins2026
Computational Discovery of MERS-CoV Main Protease Inhibitors Through Screening and Molecular Dynamics Simulations.
Article in Proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mutation-Aware Machine Learning Framework for Predicting Binding Affinity of Nirmatrelvir Analogs Targeting Coronavirus Main Proteases.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Targeting the main protease (Mpro) of coronaviruses has emerged as a promising therapeutic strategy for combating viral infections. Despite the global health threat posed by Middle East Respiratory Syndrome Coronavirus (MERS-CoV), no vaccines or antiviral drugs have been approved to date for its treatment. With a mortality rate approaching 35%, MERS-CoV remains a critical concern, particularly due to its potential for increased transmissibility through mutation. The viral main protease plays a pivotal role in the proteolytic processing of viral polyproteins, making it an attractive target for antiviral drug development. In this study, an in silico high-throughput screening was performed to identify potential inhibitors of MERS-CoV Mpro. A compound library comprising small molecules was curated from diverse sources, including DrugBank, CHEMBL, and known protease inhibitors from the Protein Data Bank. Top candidates were selected using molecular docking combined with a similarity-based search strategy, which prioritized compounds known to interact with Mpro and predicted to exhibit high binding affinity at its active site. The top-ranking candidates were further evaluated through molecular dynamics (MD) simulations to assess the conformational stability of the ligand-protein complexes. Binding free energies were subsequently calculated using multiple computational approaches, including the deep learning-based K
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.